Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iMBP-AE-201
- Development stage
- Preclinical
- Lead developer
- iMetabolic Biopharma
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
iMBP-AE-201 is a multi-domain recombinant fusion protein developed by iMetabolic Biopharma Corp. in partnership with OmniAb. It is engineered to recognize key features of chylomicron and very low-density lipoprotein (VLDL) remnant particles associated with dyslipidemias such as Hyperlipoproteinemia Type III (HLP3). The drug’s mechanism involves acting as a post-expression gene therapy that restores metabolic competency and promotes the clearance of dysfunctional lipoprotein particles from circulation. Its primary therapeutic focus is on rare lipid disorders, particularly those resulting from the ApoE2/E2 genotype, such as Hyperlipidemia Type IIa and Hyperlipoproteinemia Type III[1][3][5].
Beyond the preview
Go deeper on iMBP-AE-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iMBP-AE-201.